(Table 1).
Clinical characteristics of study participants
We extracted baseline clinical data and analyzed it descriptively for both cases and controls. Nearly a quarter (24.6%, 14) of the cases were either on ambulatory or bedridden functional status during enrollment, however, this happens for about eight percent of the controls (7.9%, 9). 84.2% (48) among the cases and 97.4% (111) of the controls were categorized under either WHO clinical stage I or II. The majority among the cases (68.4%, 39) had a baseline CD4 count <200 cells/µl, while the majority of the controls (60.5%, 69) had a baseline CD4 count >200 cells/µl. Besides, 19.3% (11) of the cases and 6.1% (7) of the controls were anemic at the time of enrollment. Likewise, 42.1% (24) of the cases and 27.2% (31) of the controls were under nutritional status at the baseline. About 21.1% (12) of the cases had a history of previous TB infection, while this is true for 3.5% (4) of the controls. About 15.8% (9) of the cases 36.8% (42) of the controls took the complete isoniazid preventive treatment. In the end, more than half of the cases (52.6%, 30) cases took ART less than a year before they develop TB, however, 71.1% (81) of the controls took the ART for more than 36 months (Table 2).
The median CD4 count among the cases and the controls were 145.00 (IQR, 80-245) and 224.50 (IQR, 123.75-288.00) respectively. The median Hgb value among the cases and the controls were 12.4 (IQR, 10.5-13.95) and 13.85 (IQR=12.70-15.00) respectively. The median length of stay on ART was 8.57 (2.89-34.97) and 53.67 (33.00-60.36) months, respectively